Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：English   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Publisher：株式会社医学書院  

DOI： 10.11477/mf.1410215296

CiNii Research

Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.ajo.2024.09.023.

Language：English  

DOI： 10.1016/j.ajo.2024.09.023

PubMed

Publisher：金原出版  

DOI： 10.18888/ga.0000003730

CiNii Research

Language：English   Publisher：Japanese Journal of Ophthalmology  

Purpose: To evaluate the clinical features and prognosis of conjunctival melanoma in Japanese patients. Study design: Retrospective observational case series. Methods: Twenty patients (8 men and 12 women) diagnosed with conjunctival melanoma at a singlehospital between 2003 and 2017 were analyzed. Data on clinical presentation, sex, age, the affected eye, tumor location, tumor origin, tumor stage according to the American Joint Committee on Cancer staging system (eighth edition), treatment, outcomes, local recurrence, metastasis, and survival were extracted from the patients’ medical records and reviewed. Results: The mean age at diagnosis was 64.2 ± 14.8 years. Tumor locations at the first examination included the bulbar conjunctiva (n = 19), plica (n = 13), and fornix (n = 12). The tumor stage was T1 in 5 cases (25%), T2 in 12 cases (60%), T3 in 3 cases (15%), and T4 in none. The mean follow-up duration was 91.7 ± 46.0 months. The local recurrence rates at 1, 5, and 10 years were 5.0%, 18.8%, and 31.5%, respectively, whilst the metastasis rates were 5.0%, 25.6%, and 32.4%, respectively. Four of the 6 patients who experienced metastasis died; duration from metastasis to death was 17.5 months (range, 7–25). The 5-year survival rate for conjunctival melanoma was 78.8%. Tumor thickness was significantly associated with survival duration on univariate Cox regression analyses. Conclusion: The mortality rate for conjunctival melanoma in the Japanese population was lower and higher than that reported in the Chinese and United States populations, respectively. Tumor thickness was a prognostic factor for survival in patients with conjunctival melanoma.

DOI： 10.1007/s10384-024-01085-z

Web of Science

Scopus

PubMed

Publisher：金原出版  

DOI： 10.18888/ga.0000003699

CiNii Research

Language：English   Publisher：Journal of Allergy and Clinical Immunology  

Background: IgG4-related disease (IgG4-RD), an example of a type I immune disease, is an immune-mediated fibrotic disorder characterized by dysregulated resolution of severe inflammation and wound healing. However, truly dominant or pathognomonic autoantibodies related to IgG4-RD are not identified. Objective: We sought to perform single-cell RNA sequencing and T-cell receptor and B-cell receptor sequencing to obtain a comprehensive, unbiased view of tissue-infiltrating T and B cells. Methods: We performed unbiased single-cell RNA-sequencing analysis for the transcriptome and T-cell receptor sequencing and B-cell receptor sequencing on sorted CD3+ T or CD19+ B cells from affected tissues of patients with IgG4-RD. We also conducted quantitative analyses of CD3+ T-cell and CD19+ B-cell subsets in 68 patients with IgG4-RD and 30 patients with Sjögren syndrome. Results: Almost all clonally expanded T cells in these lesions were either Granzyme K (GZMK)-expressing CD4+ cytotoxic T cells or GZMK+CD8+ T cells. These GZMK-expressing cytotoxic T cells also expressed amphiregulin and TGF-β but did not express immune checkpoints, and the tissue-infiltrating CD8+ T cells were phenotypically heterogeneous. MKI67+ B cells and IgD−CD27−CD11c−CXCR5− double-negative 3 B cells were clonally expanded and infiltrated affected tissue lesions. GZMK+CD4+ cytotoxic T cells colocalized with MKI67+ B cells in the extrafollicular area from affected tissue sites. Conclusions: The above-mentioned cells likely participate in T-B collaborative events, suggesting possible avenues for targeted therapies. Our findings were validated using orthogonal approaches, including multicolor immunofluorescence and the use of comparator disease groups, to support the central role of cytotoxic CD4+ and CD8+ T cells expressing GZMK, amphiregulin, and TGF-β in the pathogenesis of inflammatory fibrotic disorders.

DOI： 10.1016/j.jaci.2023.11.916

Web of Science

Scopus

PubMed

Language：Japanese   Publisher：眼科臨床紀要会  

目的:甲状腺眼症の上下斜視に対する下直筋後転術の手術成績,および手術時の患者背景について報告する.対象および方法:対象は2016～2022年に,九州大学病院で甲状腺眼症と診断し,下直筋後転術を施行した15例である.手術時のプレドニゾロン(PSL)内服量,磁気共鳴画像冠状断における下直筋断面積,術前後の遠見眼位,正面視での術後複視の有無を後ろ向きに検討した.結果:手術時のPSL内服量は1.67±3.4mg/day,下直筋面積は53.4±20.7mm2,矯正効果は4.8±1.5Δ/mmであった.下直筋面積が大きいほど術前斜視角も有意に大きく(p=0.04),術前斜視角が大きいほど1mmあたりの矯正効果も有意に大きくなった(p=0.02).術後,正面視での複視は全例で消失した.結論:術前の下直筋面積や斜視角が大きい症例では,予測よりも矯正効果が大きくなることが示唆された.(著者抄録)

Language：English   Publisher：American Journal of Ophthalmology Case Reports  

Purpose: Primary orbital liposarcomas are rare. To the best of our knowledge, only four cases of primary dedifferentiated liposarcomas of the orbit have been reported. Furthermore, there have been no reports of primary orbital liposarcomas transitioning from a highly differentiated to a dedifferentiated form. Here, we report a case of primary orbital liposarcoma that was well-differentiated at the time of initial resection at our hospital but had dedifferentiated on recurrence 10 years after the initial resection. Observations: The patient was diagnosed with an inflammatory mass after an initial tumor resection by a previous physician at age 52. Thereafter, there were four recurrences (first to fourth recurrences), and the patient underwent five surgeries and radiotherapy. For the fifth recurrence, he first visited our hospital at age 64 and was diagnosed with a well-differentiated liposarcoma after undergoing tumor resection. When the tumor recurred 9 years later (the sixth recurrence), it was well-differentiated. When the tumor recurred (the seventh recurrence) six months after surgery at the age of 73 years, the patient underwent orbital exenteration because of rapid tumor growth, and pathological examination showed that the tissue had changed to a dedifferentiated liposarcoma. Conclusions and Importance: Primary well-differentiated orbital liposarcoma may transform to a dedifferentiated form over time. The risk of dedifferentiation at recurrence should be considered in developing a treatment plan, even if the initial pathology is a well-differentiated liposarcoma.

DOI： 10.1016/j.ajoc.2023.101983

Scopus

PubMed

Language：Japanese   Publisher：(公社)日本視能訓練士協会  

【目的】外斜視を伴うdouble elevator palsyに対しKnapp法および水平筋前後転術を施行した症例を報告する。【症例】19歳女性。左眼瞼下垂の手術目的で当科受診。初診眼位は30Δ外斜視、50Δ左下斜視で左眼上転障害と左眼瞼下垂がみられた。左Knapp法と右内直筋前転、右外直筋後転術を施行し、4ヵ月後左眼下直筋後転術、上眼瞼挙筋短縮術を施行。術後眼位は、10Δ左下斜視で、術後7年の眼位は4Δ内斜視、14Δ左上斜視と上下逆転がみられた。【結論】Knapp法による矯正効果は経過とともに増強し、上下偏位の逆転が生じる可能性があるため、治療効果判定に長期経過観察を要する。(著者抄録)

Language：English   Publisher：Retina  

Purpose: To evaluate high-risk histopathological features (HRHF) following primary enucleation of eyes with retinoblastoma (RB) and assess the patient outcomes across continents Methods: Retrospective study of 1426 primarily enucleated RB eyes from five continents Results: Of all, 923 (65%) were from Asia (AS), 27 (2%) from Australia (AUS), 120 (8%) from Europe (EUR), 162 (11%) from North America (NA), and 194 (14%) from South America (SA). Based on the continent (AS vs. AUS vs. EUR vs. NA vs. SA), the histopathology features included massive choroidal invasion (31% vs. 7% vs. 13% vs. 19% vs. 27%, p=0.001), post-laminar optic nerve invasion (27% vs. 0% vs. 16% vs. 21% vs. 19%, p=0.0006), scleral infiltration (5% vs. 0% vs. 4% vs. 2% vs. 7%, p=0.13), and microscopic extrascleral infiltration (4% vs. 0% vs. <1% vs. <1% vs. 4%, p=0.68). Adjuvant chemotherapy with/without orbital radiotherapy was given in 761 (53%) patients. Based on Kaplan-Meier estimates in different continents (AS vs. AUS vs. EUR vs. NA vs. SA), the 6-year risk of orbital tumor recurrence was 5% vs. 2% vs. 0% vs. 0% vs. 12% (p<0.001), systemic metastasis was reported in 8% vs. 5% vs. 2% vs. 0% vs. 13% (p=0.001), and death in 10% vs. 3% vs. 2% vs. 0% vs. 11% (p<0.001) patients. Conclusion: There is a wide variation in the infiltrative histopathology features of RB across continents, resulting in variable outcomes. SA and AS had a higher risk of orbital tumor recurrence, systemic metastasis, and death compared to AUS, EUR, and NA.

DOI： 10.1097/IAE.0000000000004250

Scopus

PubMed

Web of Science

Language：English   Publisher：In Vivo  

Background/Aim: Lacrimal sac tumors are rare tumor types, with a long time interval from disease onset to diagnosis. We aimed to investigate the characteristics and outcomes of patients with lacrimal sac tumors. Patients and Methods: The medical records of 25 patients with lacrimal sac tumors initially treated at the Kyushu university hospital from January 1996 to July 2020 were reviewed. Results: Our analysis included 3 epithelial benign tumors (12.0%) and 22 malignant (88.0%) tumors (squamous cell carcinoma, n=6; adenoid cystic carcinoma, n=2; sebaceous adenocarcinoma, n=2; mucoepidermoid carcinoma, n=1; malignant lymphoma, n=10). The average time from symptom onset to diagnosis was 14.7 months (median=8 months; range=1-96 months). The analysis of patients revealed that lacrimal sac mass (22/25, 88.0%) was the most frequent symptom and a possible tumor marker. Most epithelial benign (n=3) and malignant epithelial (n=12) tumors were treated surgically (14/15, 93.3%). One malignant case was treated with heavy ion beam therapy. Eight patients were treated with postoperative (chemo)radiation therapy because of positive surgical margins (including one unanalyzed case). Local control was ultimately achieved in all but one case. The patient survived for 24 months with immune checkpoint inhibitors and subsequent chemotherapy for local and metastatic recurrence. Conclusion: We report our experience in the diagnosis and treatment of lacrimal sac tumors and analyze the clinical trends in cases involving these tumors. Postoperative radiotherapy and pharmacotherapy, including immune checkpoint inhibitors, may be useful for recurrent cases.

DOI： 10.21873/invivo.13198

Web of Science

Scopus

PubMed

Language：Japanese   Publisher：JAPANESE ASSOCIATION OF CERTIFIED ORTHOPTISTS  

<p> <b>【Purpose】</b>To report a case of double elevator palsy, which was accompanied by exotropia (XT) and treated with the Knapp procedure and anterior-posterior transposition of the horizontal muscle.</p><p> <b>【Case】</b>The patient in this case was a 19-year-old female. She came to our department for a left droopy eyelid surgery. Her initial eye positions were 30 prism diopters (PD) of XT and 50 PD of left hypotropia. Limited elevation and ptosis of the left eye were observed. A left Knapp procedure, right medial rectus advancement, and right lateral rectus recession were performed. Four months later, the patient underwent left inferior rectus recession and upper eyelid levator shortening. Her postoperative eye position was 10 PD of left hypotropia. At postoperative 7 years, the eye position was 4 PD of esotropia and 14 PD of left hypertropia, an inversion of the preoperative left hypotropia.</p><p> <b>【Conclusion】</b>The corrective effect of the Knapp procedure increases over time and may cause a reversal of vertical deviation, suggesting that a long-term follow-up is required to determine the treatment effect.</p>

DOI： 10.4263/jorthoptic.53f106

CiNii Research

Language：English   Publisher：Orbit (London)  

Here, we report a case of an orbital solitary fibrous tumor (SFT) with multiple local recurrences, even after orbital exenteration, and lung metastases after 41 years. The report discusses the clinical and histopathological findings of this case. A 34-year-old female patient with an orbital SFT was treated with orbital exenteration after local resection failed to prevent a recurrence. Ten years later, the patient underwent radiation therapy, followed by two rounds of gamma knife treatment, leading to remission. Forty-one years after the first treatment, the patient, at the age of 75 years, was found to have lung metastases along with orbital recurrence for the eighth time. The patient underwent radiation therapy but died from radiation pneumonitis. Our case emphasizes the need for long-term follow-up of patients with orbital tumors, even after orbital exenteration, to monitor for metastasis.

DOI： 10.1080/01676830.2021.1954665

Web of Science

Scopus

PubMed

Language：Japanese   Publisher：(公財)日本眼科学会  

背景:炎症性筋線維芽細胞性腫瘍(IMT)は筋線維芽細胞の増殖と炎症細胞浸潤を特徴とする中間悪性腫瘍であり,肺,腹腔骨盤内,後腹膜に好発し,眼窩に発生することはまれである.今回,眼窩に発生したIMTの1例を経験したので報告する.症例:46歳,女性.複視を主訴に近医眼科を受診し,眼窩に腫瘍を指摘され九州大学病院眼科を紹介受診した.初診時に右眼球結膜下の赤色調腫瘤および画像診断で右眼窩内下方に35×20×15mmの紡錘形腫瘤を認め,眼球運動障害を来していた.結膜下の腫瘤を生検したところ,炎症細胞浸潤を伴った紡錘形細胞の増殖を認めた.免疫染色の結果,増殖細胞はanaplastic lymphoma kinase(ALK),α-平滑筋アクチン(α-SMA),desmin陽性であり,IMTと診断した.結膜切開および鼻内視鏡下にアプローチして全摘出し,術後24ヵ月の現在,再発は認めていない.結論:眼窩腫瘍で非上皮性腫瘍を疑う際はIMTの可能性も検討する必要がある.(著者抄録)

Language：English   Publisher：American Journal of Surgical Pathology  

High-risk human papillomavirus (HPV) infection in conjunctival and lacrimal sac squamous cell carcinomas (SCCs) has been sporadically reported; however, its prevalence, clinicopathologic significance and surrogate markers have not been fully elucidated. Here, we attempted to clarify these questions in Japanese patients with conjunctiva and lacrimal sac SCCs. We retrospectively collected 51 conjunctival SCC and 7 lacrimal sac SCC samples and analyzed them for (1) transcriptionally active high-risk HPV infection using messenger RNA in situ hybridization and (2) protein expressions of p16 and Rb using immunohistochemistry (IHC). Among a total of 58 cases, 25 (43.1%) and 16 (27.6%) tumors were positive for p16-IHC and HPV in situ hybridization, respectively. Ten (19.6%) of the 51 conjunctival SCCs, especially in the palpebral conjunctiva, and 6 (85.7%) of the 7 lacrimal sac SCCs were positive for high-risk HPV. High-risk HPV infection was significantly associated with younger patients, nonkeratinizing SCC histology, p16-positivity and partial loss of Rb expression, but not with recurrence risk. Notably, p16-IHC was not a perfect surrogate marker for high-risk HPV infection; only 64% (16/25) of p16-positive tumors were positive for high-risk HPV. In contrast, the p16+/Rb partial loss pattern was exclusively correlated with high-risk HPV-positivity. The results suggest that the combination of p16 and Rb expression patterns by IHC could be a useful method to predict high-risk HPV infection in conjunctival and lacrimal sac SCCs. HPV infection may be of less prognostic value in this field of cancers.

DOI： 10.1097/PAS.0000000000001857

Web of Science

Scopus

PubMed

Language：English   Publisher：Ocular Oncology and Pathology  

Angiosarcoma is a widely known neoplasm with one of the poorest prognoses; however, such cases are rarely observed by the ophthalmologists in clinical practice. The tumor commonly develops on the face and scalp and may cause eyelid swelling. We present 2 such cases. Case 1 was an 82-year-old woman who presented with indulated swelling of the right eyelid that extended to the upper forehead. Biopsy revealed a poorly circumscribed tumor infiltrated throughout the dermis and fat tissue, exhibiting both angiomatous and solid patterns. Immunohistochemistry showed CD31(-) and D2-40/podoplanin(+), suggesting angiosarcoma. The patient had multiple lung metastases and died 14 months later. Case 2 was a 77-year-old man who presented with swelling of the left eyelid, and erythema on the left temporal skin developed ulcerated nodules. Biopsy showed proliferated tumor cells in a sheet form, extensively throughout the dermis. Angiosarcoma was preferred based on immunohistochemistry: CD31(+), CD34(+), and D2-40(-). The patient was treated with electron beam therapy and chemotherapy and died after 13 months. It would be difficult for an ophthalmologist to suspect such a rare neoplasm only from swelling of the eyelids. However, angiosarcoma should be considered if the swelling spreads steadily from a head rash with a nodule or ulcer nearby.

DOI： 10.1159/000520293

Web of Science

Scopus

PubMed

Language：English   Publisher：JAMA Ophthalmology  

Importance: High-risk histopathologic features of retinoblastoma are useful to assess the risk of systemic metastasis. In this era of globe salvage treatments for retinoblastoma, the definition of high-risk retinoblastoma is evolving. Objective: To evaluate variations in the definition of high-risk histopathologic features for metastasis of retinoblastoma in different ocular oncology practices around the world. Design, Setting, and Participants: An electronic web-based, nonvalidated 10-question survey was sent in December 2020 to 52 oncologists and pathologists treating retinoblastoma at referral retinoblastoma centers. Intervention: Anonymized survey about the definition of high-risk histopathologic features for metastasis of retinoblastoma. Main Outcomes and Measures: High-risk histopathologic features that determine further treatment with adjuvant systemic chemotherapy to prevent metastasis. Results: Among the 52 survey recipients, the results are based on the responses from 27 individuals (52%) from 24 different retinoblastoma practices across 16 countries in 6 continents. The following were considered to be high-risk features: postlaminar optic nerve infiltration (27 [100%]), involvement of optic nerve transection (27 [100%]), extrascleral tissue infiltration (27 [100%]), massive (≥3 mm) choroidal invasion (25 [93%]), microscopic scleral infiltration (23 [85%]), ciliary body infiltration (20 [74%]), trabecular meshwork invasion (18 [67%]), iris infiltration (17 [63%]), anterior chamber seeds (14 [52%]), laminar optic nerve infiltration (13 [48%]), combination of prelaminar and laminar optic nerve infiltration and minor choroidal invasion (11 [41%]), minor (<3 mm) choroidal invasion (5 [19%]), and prelaminar optic nerve infiltration (2 [7%]). The other histopathologic features considered high risk included Schlemm canal invasion (4 [15%]) and severe anaplasia (1 [4%]). Four respondents (15%) said that the presence of more than 1 high-risk feature, especially a combination of massive peripapillary choroidal invasion and postlaminar optic nerve infiltration, should be considered very high risk for metastasis. Conclusions and Relevance: Responses to this nonvalidated survey conducted in 2020-2021 showed little uniformity in the definition of high-risk retinoblastoma. Postlaminar optic nerve infiltration, involvement of optic nerve transection, and extrascleral tumor extension were the only features uniformly considered as high risk for metastasis across all oncology practices. These findings suggest that the relevance about their value in the current scenario with advanced disease being treated conservatively needs further evaluation; there is also a need to arrive at consensus definitions and conduct prospective multicenter studies to understand their relevance..

DOI： 10.1001/jamaophthalmol.2021.4732

Web of Science

Scopus

PubMed

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese   Publishing type：Research paper (scientific journal)  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Responsible for pages：OCULISTA 70:32-38   Language：Japanese  

Responsible for pages：眼科 60:1091-1099   Language：Japanese  

Responsible for pages：田邉美香; 臨床眼科 第72巻　第2号:208-219   Language：Japanese  

Responsible for pages：眼科グラフィック 第7巻1号:17-20   Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Event date： 2021.6

Language：Japanese  

Venue：山口県   Country：Japan  

Event date： 2021.5

Language：Japanese  

Venue：愛媛県   Country：Japan  

Event date： 2021.4

Language：Japanese  

Venue：大阪府   Country：Japan  

Event date： 2021.4

Language：Japanese  

Venue：大阪府   Country：Japan  

Event date： 2022.5

Language：Japanese  

Venue：沖縄県   Country：Japan  

Event date： 2022.4

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2021.11

Language：Japanese  

Venue：静岡県   Country：Japan  

Event date： 2021.10

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2021.10

Language：Japanese  

Country：Japan  

Event date： 2021.9

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2021.9

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2021.9

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2021.9

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2021.9

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2021.9

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2021.5

Language：Japanese  

Venue：愛媛県   Country：Japan  

Event date： 2021.5

Language：Japanese  

Venue：佐賀県   Country：Japan  

Event date： 2021.2

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2021.2

Language：Japanese  

Country：Japan  

Event date： 2020.10

Language：Japanese  

Venue：東京都   Country：Japan  

Event date： 2020.10

Language：Japanese  

Country：Japan  

Event date： 2020.10

Language：Japanese  

Country：Japan  

Event date： 2020.9

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.6

Language：Japanese  

Country：Japan  

Event date： 2020.5 - 2021.5

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2020.5

Language：Japanese  

Venue：福岡県   Country：Japan  

Event date： 2020.4

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2019.6

Language：Japanese  

Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：沖縄   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：沖縄   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：大阪府   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡県   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡県   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡県   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京都   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京都   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：東京都   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：東京都   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡県   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：福岡県   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (general)  

Venue：愛知県   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Oral presentation (invited, special)  

Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：福岡県   Country：Japan  

Event date： 2018.6

Language：Japanese   Presentation type：Symposium, workshop panel (public)  

Venue：東京都   Country：Japan  

Event date： 2018.5

Language：Japanese  

Country：Japan  

Event date： 2017.5

Language：Japanese  

Country：Japan  

Event date： 2017.3

Language：Japanese  

Country：Japan  

Event date： 2017.2

Language：Japanese  

Country：Japan  

Event date： 2016.11

Language：Japanese  

Country：Japan  

Event date： 2016.10

Language：Japanese  

Country：Japan  

Event date： 2016.10

Language：Japanese  

Country：Japan  

Event date： 2016.9

Language：Japanese  

Country：Japan  

Event date： 2016.9

Language：Japanese  

Country：Japan  

Event date： 2016.9

Language：Japanese  

Country：Japan  

Event date： 2016.9

Language：Japanese  

Country：Japan  

Event date： 2016.9

Language：Japanese  

Country：Japan  

Event date： 2016.8

Language：English  

Country：Japan  

Event date： 2016.5

Language：Japanese  

Country：Japan  

Event date： 2016.5

Language：Japanese  

Country：Japan  

Event date： 2016.5

Language：Japanese  

Country：Japan  

Event date： 2016.4

Language：Japanese  

Country：Japan  

Event date： 2016.4

Language：Japanese  

Country：Japan  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese   Publisher：(株)全日本病院出版会  

代表的な眼瞼悪性腫瘍には脂腺癌、基底細胞癌、メルケル細胞癌がある。良性腫瘍では、脂腺癌、メルケル細胞癌との鑑別が重要な霰粒腫や、基底細胞癌との鑑別を要する母斑と脂漏性角化症等がある。眼瞼腫瘍の良悪性を見分けるポイントとしては、悪性腫瘍では睫毛脱落、マイボーム腺の消失、瞼板の破壊等、正常組織の破壊がみられることや、腫瘍の形状が複雑で表面不整であることが挙げられる。また、悪性の場合は不規則に走行する血管、口径不同を伴った血管が腫瘍の表層に目立つこともしばしば鑑別に有用な情報となる。悪性を疑う場合は積極的に生検を行うか、然るべき施設に紹介し、早期診断・早期治療を目指す。(著者抄録)

Language：Japanese  

Language：Japanese   Publisher：(株)全日本病院出版会  

前頭筋つり上げ術は、先天性眼瞼下垂や動眼神経麻痺等の挙筋機能が低い症例に対して行われる眼瞼下垂の術式である。眼瞼～眉毛上までトンネルを作成し、前頭筋の働きを利用して眼瞼を挙上する方法である。対象疾患の代表である先天性眼瞼下垂の治療に際して最も重要なことは、視機能発達段階であることを理解し、視機能が発達するためのサポートを行うことである。そのため術前評価では瞳孔領との位置関係のみならず、屈折や斜視等の視機能の評価を行い、必要があれば弱視治療を積極的に行う必要がある。前頭筋つり上げ術には、大腿筋膜等の自家組織で行う場合と、糸やゴアテックスシート等の人工材料で行う場合がある。ナイロン糸を用いたつり上げ術では低侵襲で手技も簡便だが術後再発率が高く、視機能のため早期に眼瞼挙上が必要な乳幼児等に対して一期的に行う手術として適しているといえる。(著者抄録)

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese